Results 11 to 20 of about 531,069 (346)

Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma

Haematologica, 2017
In the European Intergroup EURO-LB02 trial, children and adolescents with lymphoblastic lymphoma underwent the non-Hodgkin lymphoma Berlin-Frankfurt-Münster protocol without prophylactic cranial radiotherapy.
Eva Landmann, Birgit Burkhardt, Martin Zimmermann, Ulrike Meyer, Wilhelm Woessmann, Wolfram Klapper, Grazyna Wrobel, Angelo Rosolen, Marta Pillon, Gabriele Escherich, Andishe Attarbaschi, Auke Beishuizen, Karin Mellgren, Robert Wynn, Richard Ratei, Adriana Plesa, Martin Schrappe, Alfred Reiter, Christophe Bergeron, Catherine Patte, Yves Bertrand   +20 more
doaj   +2 more sources

B-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma [PDF]

American Journal of Clinical Pathology, 2015
This session of the 2013 Society of Hematopathology/European Association for Haematopathology Workshop was dedicated to B-acute lymphoblastic leukemia (B-ALL)/lymphoblastic lymphoma (LBL) with recurrent translocations and not otherwise specified.In this review, we summarize the cases discussed during the workshop, review the pertinent and most recent ...
Sanam, Loghavi, Jeffery L, Kutok, Jeffrey L, Jorgensen   +2 more
openaire   +3 more sources

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

Cancer Discovery, 2021
Combining venetoclax, a selective BCL-2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL-2 inhibitor, may allow targeting of both BCL-2 and BCL XL without dose-limiting thrombocytopenia associated with navitoclax monotherapy.
V. Pullarkat, Norman J. Lacayo, E. Jabbour, J. Rubnitz, A. Bajel, T. Laetsch, Jessica T. Leonard, Susan I. Colace, S. Khaw, S. Fleming, R. Mattison, R. Norris, J. Opferman, K. Roberts, Yaqi Zhao, Chunxu Qu, Mohamed Badawi, Michelle Schmidt, Bo Tong, John C. Pesko, Yan Sun, J. Ross, D. Vishwamitra, Lindsey Rosenwinkel, S. Y. Kim, A. Jacobson, C. Mullighan, Thomas B. Alexander, W. Stock   +28 more
semanticscholar   +1 more source

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Frontiers in Pediatrics, 2022
Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over the past five decades with now over 90% of children achieving long-term survival.
L. Maese, R. Rau
semanticscholar   +1 more source

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells

Stem Cell Reviews and Reports, 2021
While treatment for B-cell malignancies has been revolutionized through the advent of CAR immunotherapy, similar strategies for T-cell malignancies have been limited. Additionally, T-cell leukemias and lymphomas can commonly metastasize to the CNS, where
Jia Feng, Haichan Xu, Andrew Cinquina, Zehua Wu, Qi Chen, Ping Zhang, Xingen Wang, Huiming Shan, Lei Xu, Qian Zhang, Lihua Sun, Wenli Zhang, K. Pinz, M. Wada, Xun Jiang, William M. Hanes, Yupo Ma, Hongyu Zhang   +17 more
semanticscholar   +1 more source

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Cancers, 2021
Simple Summary Pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoma (LBL) currently have unsatisfactory outcomes, and novel treatment options are needed.
Amber Gibson, Adriana Trabal, D. McCall, S. Khazal, Laurie Toepfer, D. Bell, Michael Roth, K. Mahadeo, C. Nunez, N. Short, C. Dinardo, M. Konopleva, G. Issa, F. Ravandi, N. Jain, G. Borthakur, H. Kantarjian, E. Jabbour, Branko Cuglievan   +18 more
semanticscholar   +1 more source

Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma

Journal of Clinical Oncology, 2022
PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which ...
D. Teachey, M. Devidas, B. Wood, Zhiguo Chen, R. Hayashi, M. Hermiston, R. Annett, J. Archer, B. Asselin, K. August, Steve Y. Cho, K. Dunsmore, B. Fisher, J. Freedman, P. Galardy, P. Harker-Murray, T. Horton, A. Jaju, Allison Lam, Y. Messinger, R. Miles, Maki Okada, Samir Patel, E. Schafer, T. Schechter, Neelam Singh, Amii C. Steele, M. Sulis, S. Vargas, S. Winter, Charlotte Wood, P. Zweidler-McKay, C. Bollard, M. Loh, S. Hunger, E. Raetz   +35 more
semanticscholar   +1 more source

Indolent T-lymphoblastic proliferation with fibrolamellar hepatocellular carcinoma developed after colorectal adenocarcinoma: a case report

Pathology and Oncology Research, 2023
Objective: Indolent T-lymphoblastic proliferation (iT-LBP) is a non-neoplastic disease with an indolent clinical course, manifesting as hyperplasia of immature extrathymic T-lymphoblastic cells.
Wen Han, Bei Wang, Xiang Yong, Yi Zhang, Mingyu Shao, Chun Wang   +5 more
doaj   +1 more source

T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?

Blood Advances, 2020
T-cell lymphoblastic lymphoma (T-LBL) and lymphoblastic leukemia (T-ALL) represent malignancies that arise from the transformation of immature precursor T cells.
E. Kroeze, J. Loeffen, V. M. Poort, J. Meijerink   +3 more
semanticscholar   +1 more source

FIP1L1‐PDGFRA fusion gene in T‐lymphoblastic lymphoma: A case report

Cancer Reports, 2023
Background T‐lymphoblastic lymphoma (T‐LBL) is an aggressive malignancy of T‐lymphoid precursors, rarely co‐occurring with myeloid/lymphoid neoplasms with eosinophilia (M/LNs‐Eo), with consequent rearrangement of tyrosine kinase (TK)‐related genes.
Salhah Ali, Yasmine Al‐Qattan, Walaa Awny, Abdulaziz Hamadah, Karen Pinto, Salem AlShemmari   +5 more
doaj   +1 more source